Loading…
Loading…
Shares of Clariant AG (OTCMKTS:CLZNY - Get Free Report) have been assigned an average rating of "Hold" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, three have given a buy recommendation and one
Clariant AG (CLZNY) Q2 2026 Earnings Call Transcript
Clariant AG (CLZNY) Q1 2026 Earnings Call Transcript
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FIRST QUARTER | 2026 Q1 2026 sales decreased by 2 % in local currencies 1 to CHF 918 million with the Middle East conflict impacting Catalyst volumes and portfolio pruning affecting Care Chemicals; 0.5 % decline excluding portfolio pruning Q1 2026 EBITDA margin before exceptional items of 17.5 % decreased by 130 basis points compared to a strong Q1 2025 mainly due to the Middle East conflict and a one-off impacting Catalysts Q1 2026 free cash flow conversion improved by 12 percentage points to 54 % (LTM basis), achieved through effective net working capital management and continued disciplined Capex On track to achieve the remaining CHF 30 million of the total CHF 80 million performance improvement program savings (Investor Day 2024) already in 2026, with CHF 9 million achieved in the first quarter Guidance 2026 remains unchanged while Middle East conflict particularly impacting demand in our Catalysts business, causing increasing input costs, and overall elevated uncertainty and volatility “In the first quarter of 2026, Clariant delivered flat underlying sales, excluding the effects of our proactive portfolio pruning measures.
Clariant has released its Integrated Report 2025, which provides a comprehensive overview of both the company's financial and non-financial performance
Clariant AG (CLZNY) Q4 2025 Earnings Call Transcript
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FOURTH QUARTER / FULL YEAR | 2025 Q4 2025 sales increased by 1 % in local currencies 1 to CHF 1.028 billion due to strong volume growth in Catalysts and Care Chemicals Q4 2025 EBITDA margin before exceptional items increased by 240 basis points to 17.1 %, with strong profitability improvement in Catalysts and Care Chemicals FY 2025 sales of CHF 3.915 billion flat in local currencies 1 including 1 % scope (Lucas Meyer Cosmetics) FY 2025 EBITDA margin before exceptional items increased by 180 basis points to 17.8 %, driven by performance improvement programs and cost productivity across the entire organization Performance improvement program achieved CHF 50 million savings in 2025, on track to deliver CHF 80 million with the remainder largely expected in 2026 FY 2025 free cash flow conversion of 42 % increased by 10 percentage points, already achieving the medium-term target level Stable distribution of CHF 0.42 per share to be proposed to AGM on 1 April 2026 Outlook 2026: local currency sales to be around flat; EBITDA margin before exceptional items at around 18 %; medium-term targets confirmed “In 2025, Clariant delivered an EBITDA margin of 17.8 % before exceptional items, a significant year-on-year increase of 180 basis points.
Clariant AG (OTCMKTS:CLZNY - Get Free Report) has earned a consensus rating of "Reduce" from the six brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. A number of equities analysts have recently issued
No recent filings indexed.